Scisparc Ltd Acquires 55% Stake in NeuroThera
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 08 Dec 25
Source: Newsfilter
Scisparc Ltd shares rose by 9.77% as it crossed above the 5-day SMA following the acquisition news.
The company announced it will acquire a 55% stake in NeuroThera, a pioneering Israeli quantum computing bio data company, in exchange for 40% of NeuroThera's equity. This strategic move aims to enhance efficiency in bio data storage and analysis, potentially revolutionizing clinical trials.
This acquisition not only strengthens SciSparc's position in treating central nervous system disorders but also opens new market opportunities through innovative quantum intelligence technology.
Analyst Views on SPRC
About SPRC
Scisparc Ltd, former Therapix Biosciences Ltd is a Israel-based pharmaceutical company commited into creating and enhancing technologies and assets based on cannabinoid pharmaceuticals. The company is engaged in drug development programs based on repurposing a cannabinoid (Dronabinol): THX-110 for the treatment of Tourette syndrome (TS), for the treatment of Obstructive Sleep Apnea (OSA), and the treatment of Pain; THX-130 for the treatment of Mild Cognitive Impairment (MCI) and Traumatic Brain Injury (TBI); THX-150 for the treatment of infectious diseases; and THX-160 for the treatment of pain.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
